Phase 2 Trial of First-Line Therapy With Satraplatin and Paclitaxel in Patients With Unresectable Stage III or IV Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

Phase 2 Trial of First-Line Therapy With Satraplatin and Paclitaxel in Patients With Unresectable Stage III or IV Non-Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2012

At a glance

  • Drugs Paclitaxel; Satraplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors GPC Biotech Inc
  • Most Recent Events

    • 27 Apr 2012 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 15 Jul 2008 Status change
    • 03 Jun 2008 Final results presented at ASCO 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top